Algeria, Africa’s largest country by area, was hit hard by the global oil price slump of 2014. In terms of healthcare and the life sciences, the state of the country’s weakened hydrocarbon-dependent economy meant that it was forced to shutter plans to construct five brand new, state-of-the-art University Hospitals (CHUs) and step away from a massive USD 262 billion 2015-19 public healthcare infrastructure renewal program.
A turbulent few years in the domestic industry has also seen the enactment of a new, sweeping healthcare law and the imposition of import restrictions on pharmaceuticals and medical devices. Nevertheless, Algeria remains a promising investment destination for the global life sciences industry, with a sizeable local market and a growing number of multinationals choosing to base their regional operations out of Algiers.
Topics covered in this report – which featured the exclusive insights of government ministers, the heads of local pharma champions as well as multinational affiliate leaders – include the potential impact of the new healthcare law, the establishment of a National Cancer Plan, global companies’ scramble to localise manufacturing operations, an investment wave from the Middle East, and Algeria’s ramped-up export capabilities.